Evidence map›Paper›PMID 20723802›Full record

ArticleJournal of the American College of Cardiology2010

Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction.

Atta Behfar, Satsuki Yamada, Ruben Crespo-Diaz, Jonathan J Nesbitt, Lois A Rowe, Carmen Perez-Terzic, Vinciane Gaussin, Christian Homsy, Jozef Bartunek, Andre Terzic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Effect ofBioMedicine · 2022
    Article
  16. Review
  17. Mass Customized Outlook for Regenerative Heart Failure Care.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Review
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Atta BehfarDepartment of Medicine, Division of Cardiovascular Diseases, Marriott Heart Disease Research Program, Mayo Clinic, Rochester, Minnesota 55905, USA.
Satsuki Yamada
Ruben Crespo-Diaz
Jonathan J Nesbitt
Lois A Rowe
Carmen Perez-Terzic
Vinciane Gaussin
Christian Homsy
Jozef Bartunek
Andre Terzic

Funding

Regulation of cardiac nuclear pore structure and functionR01HL085208 · NHLBI · MAYO CLINIC ROCHESTER · PI TERZIC, CARMEN MILITZA · 2007 to 2011
$1.9M
Cardioprotective Repair through CardiopoiesisR01HL083439 · NHLBI · MAYO CLINIC ROCHESTER · PI TERZIC, ANDRE · 2006 to 2010
$1.8M
NHLBI NIH HHS HL83439NHLBI NIH HHS HL85208NHLBI NIH HHS R01 HL083439NHLBI NIH HHS R01 HL085208
6 · The paper itself

Abstract

objectivesThe goal of this study was to guide bone marrow-derived human mesenchymal stem cells (hMSCs) into a cardiac progenitor phenotype and assess therapeutic benefit in chronic myocardial infarction.

backgroundAdult stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart disease. Pre-emptive lineage pre-specification may optimize therapeutic outcome.

methodshMSC were harvested from a coronary artery disease patient cohort. A recombinant cocktail consisting of transforming growth factor-beta(1), bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1, fibroblast growth factor-2, alpha-thrombin, and interleukin-6 was formulated to engage hMSC into cardiopoiesis. Derived hMSC were injected into the myocardium of a nude infarcted murine model and followed over 1 year for functional and structural end points.

resultsAlthough the majority of patient-derived hMSC in their native state demonstrated limited effect on ejection fraction, stem cells from rare individuals harbored a spontaneous capacity to improve contractile performance. This reparative cytotype was characterized by high expression of homeobox transcription factor Nkx-2.5, T-box transcription factor TBX5, helix-loop-helix transcription factor MESP1, and myocyte enhancer factor MEF2C, markers of cardiopoiesis. Recombinant cardiogenic cocktail guidance secured the cardiopoietic phenotype across the patient cohort. Compared with unguided counterparts, cardiopoietic hMSC delivered into infarcted myocardium achieved superior functional and structural benefit without adverse side effects. Engraftment into murine hearts was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induction of myocardial cell cycle activity.

conclusionsGuided cardiopoiesis thus enhances the therapeutic benefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy.

Indexed as

Bone Marrow TransplantationMesenchymal Stem Cell TransplantationAnimalsBiological FactorsCell Culture TechniquesCell DifferentiationCell LineageHomeobox Protein Nkx-2.5Homeodomain ProteinsHumansMADS Domain ProteinsMEF2 Transcription FactorsMesenchymal Stem CellsMiceMice, NudeMolecular MimicryBiological FactorsHomeobox Protein Nkx-2.5Homeodomain ProteinsMADS Domain ProteinsMEF2C protein, humanMEF2 Transcription FactorsMyogenic Regulatory FactorsNKX2-5 protein, humanT-Box Domain ProteinsT-box transcription factor 5Transcription Factors

Identifiers

PMID20723802
PMCPMC2932958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.